Physician profile
Eliana Ege
NPI 1083240071
$5,247.09
in general payments reported to CMS, 2019-2025
14 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 80% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $296 · 2023: $722 · 2024: $2,107 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Travel and Lodging: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.43 |
| Travel and Lodging | $1,047.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,389.76 | 2024-2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $1,212.87 | 2024-2025 | Sprint Pns System |
| Nevro Corp. | $701.28 | 2022-2024 | Senza |
| Medtronic, INC. | $676.84 | 2023-2025 | Vanta Adaptivestim, Synchromedii, Vectris Surescan |
| Stratus Medical, LLC | $341.01 | 2024-2025 | Nimbus |
| Boston Scientific Corporation | $300.91 | 2022-2025 | Intracept |
| Novo Nordisk INC | $124.98 | 2023 | Wegovy |
| Glaxosmithkline, LLC. | $120.23 | 2023 | Bexsero |
| Saluda Medical Americas, INC. | $116.95 | 2024 | Evoke |
| Mml US, INC. | $93.40 | 2025 | Reactiv8 |
| Amgen INC. | $93.30 | 2024 | Repatha |
| Stryker Corporation | $42.76 | 2025 | Omnicurve, Mild Device Kit |
| Curonix LLC | $18.64 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $14.16 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliana Ege listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.